ApoGen Biotechnologies

ApoGen Biotechnologies is developing novel oncology therapeutics targeting the key drivers of mutation and cancer genomic evolution to overcome drug resistance. Our lead target is APOBEC3B (A3B), a DNA cytosine deaminase and an important endogenous source of DNA mutation in cancer. A3B was recently identified as a dominant source of the characteristic C-to-T mutational pattern and higher overall mutational load seen in numerous cancers. Elevated levels of A3B were shown to be a key driver in the formation of cancers including breast, head and neck, lung, bladder, cervical, ovarian, myeloma, and some blood cancers. ApoGen’s drug discovery and development efforts are directed toward highly selective and potent small molecule inhibitors of A3B. These inhibitors aim to slow or stop cancer genome mutation and the development of drug resistance, potentially increasing the effectiveness of current and future therapies.
Type
Private
HQ
Seattle, US
Founded
2014
Employees
2 (est)
ApoGen Biotechnologies was founded in 2014 and is headquartered in Seattle, US

ApoGen Biotechnologies Locations

Seattle, US

ApoGen Biotechnologies Metrics

ApoGen Biotechnologies Summary

Founding Date

2014

Total Funding

$7 M

Latest funding size

$7 M

Time since last funding

about 1 month

Investors

We estimate that ApoGen Biotechnologies's latest funding round in December 2016 was $7 M. In total, ApoGen Biotechnologies has raised $7 M

ApoGen Biotechnologies Company Life

You may also be interested in